Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 17:S0092-8674(25)01018-9.
doi: 10.1016/j.cell.2025.08.029. Online ahead of print.

Creeping fat-derived mechanosensitive fibroblasts drive intestinal fibrosis in Crohn's disease strictures

Affiliations

Creeping fat-derived mechanosensitive fibroblasts drive intestinal fibrosis in Crohn's disease strictures

Khristian E Bauer-Rowe et al. Cell. .

Abstract

A significant complication of Crohn's disease (CD) is intestinal fibrosis, which narrows the bowel lumen to form a stricture. Creeping fat (CF) is the wrapping of mesenteric adipose tissue around diseased bowel, of which the role in CD stricture progression is unclear. By constructing a human single-cell CD fibroblast atlas, we identified CF-derived, CTHRC1+ fibroblasts enriched for Yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) signatures and localized to a fibrotic CF-bowel wall interface within the stricture. We further showed that analogous Cthrc1+ mouse fibroblasts derive from mesenteric adipose tissue stromal cells, infiltrate fibrotic bowel, and deposit extracellular matrix in a YAP/TAZ-dependent manner in a mouse model of intestinal fibrosis. Our findings identify CF as a key source of pro-fibrotic fibroblasts and raise the possibility of improving future clinical management of stricture progression by targeting not only the bowel but also CF.

Keywords: Crohn’s disease; Yes-associated protein; creeping fat; fibroblasts; fibrosis; inflammatory bowel disease; meta-analysis; scRNA-seq; strictures.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.L.N. is on the SAB of Seed Inc. and is a co-founder of Stara Biosciences. Stanford Provisional patent: “YAP Inhibition for Intestinal Fibrosis,” serial number 63/818,707 (M.T.L., J.S.H., A.K., B.P., N.E.L., and K.E.B.-R.).

References

    1. D’Alessio S, Ungaro F, Noviello D, Lovisa S, Peyrin-Biroulet L, and Danese S (2022). Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nat Rev Gastroenterol Hepatol 19, 169–184. 10.1038/s41575-021-00543-0. - DOI - PubMed
    1. Chaparro M, Garre A, Ricart E, Iglesias-Flores E, Taxonera C, Domènech E, Gisbert JP, and ENEIDA study group (2019). Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Aliment Pharmacol Ther 49, 419–428. 10.1111/apt.15114. - DOI - PubMed
    1. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, et al. (2008). Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology 135, 1106–1113. 10.1053/j.gastro.2008.06.079. - DOI - PubMed
    1. Patel HI, Leichtner AM, Colodny AH, and Shamberger RC (1997). Surgery for Crohn’s disease in infants and children. J Pediatr Surg 32, 1063–1067; discussion 1067–1068. 10.1016/s0022-3468(97)90400-0. - DOI - PubMed
    1. Schaefer ME, Machan JT, Kawatu D, Langton CR, Markowitz J, Crandall W, Mack DR, Evans JS, Pfefferkorn MD, Griffiths AM, et al. (2010). Factors that determine risk for surgery in pediatric patients with Crohn’s disease. Clin Gastroenterol Hepatol 8, 789–794. 10.1016/j.cgh.2010.05.021. - DOI - PubMed

LinkOut - more resources